Full Text
HPR238 What Does the New ILAP Refresh Mean for Pharmaceutical Development and Patient Access in the UK?

Abstract

Authors

Georgie Johnson Sarah Campbell-Hill Amy Whyte Andy Boateng

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×